Abstract Hereby, we report the case of a 12-year-old girl developing oligoarthritis and progressing into a polyarticular form. Rheumatoid factor was positive, and juvenile idiopathic arthritis (JIA) was diagnosed. After a poor response to DMARDs, an anti-TNF agent (infliximab) was initiated, but to be discontinued due to an allergic reaction. The same complication was observed with the fully human derivative, adalimumab. At the age of 22, the patient presented septicemia with severe anemia and subsequent development of leukopenia, myocarditis with heart failure, and ANA, aSm, aSS-A, aCL positives, and nephrotic syndrome. These new clinical manifestations fulfilled the classification criteria for the diagnosis of systemic lupus erythematosus. Due to the poor therapeutic responses for both diseases, alternative medical options have to be considered, such as targeted therapy with anti-CD20 or interleukin-6 receptor antagonist monoclonal antibodies. This patient may also be a candidate for autologous hemopoietic stem cell transplantation.
Introduction
Juvenile idiopathic arthritis (JIA) encompasses of a heterogeneous group of disorders with unknown etiology that usually starts before the age of 16 and persists for at least 6 weeks. It is characterized by the persistent swelling of one or more joints [1] . This autoimmune disorder is a major cause of chronic disability in children. Although the onset and disease course may differ, all subtypes of JIA share the occurrence of chronic inflammation of the joints [2] . Arthritis affecting 4 or fewer joints during the first 6 months of the disease is denoted as pauci-articular by the European league Againt Rheumatism (EULAR) [3, 4] or oligoarticular by International League of Association for Rheumatology (ILAR) [5, 6] .
The ILAR classification of JIA and oligoarthritis is further characterized, as either persistent (no more than four joints are affected during the disease course), or extended (if, after the initial 6-month period, the total number of affected joints is more than four) oligoarticular forms. Polyarthritis affects primarily more than four joints during the first 6 months of the disease course and further subclassified as rheumatoid factor (RF) negative, or, if RF is detected on two occasions at least 3 months apart, RF positive [3] [4] [5] .
Polyarthritis accounts for approximately 30% of patients with JIA. Children with RF-positive polyarticular JIA have late onset in childhood or adolescence. In this patients often develop symmetric, small and large joint involvement that resembles adult RA, with rheumatoid nodules, early onset of erosive synovitis, and chronic disease course persisting into adulthood [7, 8] . Systemic manifestations in children with polyarthritis include low-grade fever, anorexia, growth failure, and weight loss [9] . Fatigue may be a prominent symptom. Slight-to-moderate hepato-splenomegaly or lymph node enlargement may be present, but these are less prominent compared to children with systemic JIA [10] . Biological agents have been designed to target particular immunologically active molecules, which play role in the pathogenesis of disease. Until now, the tumor necrosis factor alpha (TNF-a) blockers, etanercept, and adalimumab are approved for the treatment of active polyarticular JIA, and these drugs have dramatically improved disease outcome as well as quality of life [11, 12] .
Systemic lupus erythematosus (SLE) is a multifactorial systemic autoimmune disease characterized by heterogenous clinical manifestations; e.g., skin symptoms, polyarthritis, serositis, neuropsychiatric symptoms, kidney disease, hematological abnormalities, and the presence of different antinuclear and other autoantibodies. Despite the survival and treatment options of SLE have improved markedly, its morbidity and treatment-related adverse effects are still considerable [13] . Although the exact causes of lupus are unknown, some trigger factors-such as the use of anti-TNF inhibitors-have already been confirmed in the pathomechanism, which could trigger the appearance of other antibodies against double stranded DNA (a-dsDNA) as well as anti-cardiolipin antibodies (aCL) [14] .
This case report focuses on the overlap syndromes that may occur not only in adults but in childhood. Clinical features, inadequate therapeutic responses make us to demonstrate that careful monitoring is important and besides various biological treatments, other therapeutic options might be essential. However, it is also important to provide the optimal treatment modality for such patients that is beneficial for both diseases
Case report
We report a case of a Caucasian girl, who was first admitted to our hospital in 1997 (at the age of 12) with oligoarticular onset of JIA. The immune serology was positive for RF and ANA, while a-dsDNA was negative, as well as HLA-B27. It was not possible to measure anticitrullinated peptide antibody (aCCP) at that time.
Between 1997 and 2003, sulfasalazine, methotrexate, leflunomide, cyclosporin A, corticosteroids, and non-steroidal anti-inflammatory drugs (NSAID) were administered without any long-standing therapeutic effect. Increasing the number of the joints involved, the disease progressed into an erosive polyarticular form. Because of the permanent and severe disease activity, the patient was eligible to be involved into a randomized double-blind controlled intrapatient dose escalation phase II trial of infliximab in 2003. The treatment had to be discontinued due to an allergic reaction occurring within 3 months of initiating the therapy. Between 2003 and 2006, various disease-modifying anti-rheumatic drugs (DMARDs), local and systemic corticosteroids were used with poor efficacy. Side effects, such as leukopenia, peptic ulcer, and hair loss, were also present. In 2007, the patient developed an E. coli septicemia with severe anemia and toxic cardiomyopathy resulting in heart failure. Within the following 8 weeks, leukopenia and different autoantibodies, namely ANA, antibodies against Smith antigen (aSm), and Sjögren syndrome A antigen (aSS-A) as well as anti-cardiolipin (aCL), appeared. Nephrotic syndrome developed, and kidney biopsy proved an ISN/RPS type II lupus nephritis. The patient fulfilled the diagnostic criteria of SLE, established by the American College of Rheumatology and modified in 1997 [15] . Together with appropriate antibiotic therapy, corticosteroids and later azathioprine were administered, which resulted in partial remission. Lupus nephritis relapsed one year later with nephrotic syndrome, microscopic hematuria, high anti-dsDNA concentration accompanied with hypocomplementemia. The patient refused kidney rebiopsy, but the histopathological progression was feasible. Therefore, six cycles of intravenous pulse cyclophosphamide were given and resulted in a partial remission again as indicated by the fall of proteinuria from 10 g to 1 g per day. However, after a few months with corticosteroid and azathioprine maintenance therapy, the disease relapsed again. At the same time, we observed the deterioration of joint inflammation with a progressively increasing number of bone erosions and joint space narrowing, typically consistent with JIA. RF was normal, while aCCP level was significantly high. The progression of both diseases requires new therapeutic decision.
Discussion
The coexistence of two or more autoimmune diseases in the same patient occurs with variable frequency, but relatively rarely [16] . Some genetic studies have identified various loci associated with increased risk for both RA and SLE, along with candidate genes associated with predisposition to autoimmune diseases in general [17] , supporting the hypothesis of ''shared autoimmunity''. These results suggest a common and specific genetic background. However, if the classification criteria of the systemic diseases are not fulfilled initially, the early symptoms refer to the coexisting diseases [18, 19] . Synovitis and arthritis are typical features of almost all inflammatory rheumatic disorders, but the localization and the extent of the inflamed joints and erosions could help in the differential diagnosis. Erosive arthritis in SLE is unusual, and only a minority of patients develop deforming a non-erosive, RF-negative process, denoted as ''Jaccoud's arthropathy'' [20] . The RF and aCCP levels correlate directly with the disease activity in RA, but not in SLE. Although CRP is also a marker of disease activity in systemic JIA and RA, it may also act as an active pathogenic agent for an erosive arthritis pattern among SLE patients [21] .
It is likely that genetic polymorphisms play an important role, particularly in RF-positive polyarthritis [7] . The onset of polyarthritis in a pre-adolescent or adolescent girl should suggest the possible diagnosis of SLE. The arthritis may mimic that of JIA. Its clinical manifestations are extremely variable, and its natural history is unpredictable [22] . Without serological markers with the clinical hallmarks of SLE, the exact diagnosis may be difficult.
There are further unusual and critical points in this case, namely the arthritis appeared first as an oligoarticular type and then progressed into a polyarticular form, together with severe kidney, heart, and hematological involvements. Pericarditis or pleuritis are infrequent in JIA [23, 24] ; cardiac valve disease and glomerulonephritis are uncommon complications in RF-positive polyarthritis [25] [26] [27] . The rapid progression and variable organ manifestations may confirm the hypothesis of the complete dysregulation of the immune system. The third cause could be the side effect of the anti-TNF therapy; the biological therapy might induce the appearance of autoantibodies and lupus symptoms in this case [14, 28, 29] . However, the patient was treated with TNF-blockers only for a short period of time because of the allergic reaction, so the cumulative doses of the two anti-TNF therapies were unlikely to be able to induce antidsDNA, or other lupus-related antibodies, such as anti-ENA, anti-histone or anti-nucleosome antibodies, and the clinically relevant lupus-like symptoms [28, 29] . Previously, it has been described that anti-TNF therapy could be a potentially effective and useful therapeutic option for SLE patients [28, 29] . Although TNF blockade was clinically effective, the majority of SLE patients treated with infliximab showed a transient increase in autoantibodies to nuclear antigens and phospholipids, without any association with disease flares. Increased availability of apoptotic antigens after TNF blockade may lead to autoantibody formation induced by this treatment regime [28, 29] . An open-label data suggest that TNF blockade suppresses inflammatory manifestations of SLE, and long-term benefit was seen in patients with lupus nephritis [28, 29] .
Anti-TNF therapies are promising new strategies in the treatment not only in adult RA but in JIA, as well [11, 14, 17, 30, 31] . Despite good clinical efficacy and tolerance, the possible occurrence of drug-induced autoimmune disorders remains a matter of concern. Induction of ANA and anti-DNA antibodies is observed in some patients treated with TNF-a inhibitors (anti-TNF-a monoclonal antibodies or soluble TNF-a receptor) possibly leading to the initiation of lupus [32, 33] .
The use of protein-based anti-TNF-a therapies such as antibodies and soluble TNF-a receptors is commonly associated with the induction of autoantibodies, whereas anti-TNF-induced lupus (ATIL) is rare. ATIL can occur with any of the available TNF-inhibitors, but the frequency and clinical characteristics of ATIL vary between different drugs [31] .
Conclusion
Overlap syndromes may occur not only in adulthood but in children, as well [15] . There are a few publications about JIA ? SLE associations overviewing the consequences of this particular overlap [34] [35] [36] . The thorough follow-up and monitoring of laboratory parameters and organ functions is of utmost importance in order to diagnose the early detection of serious manifestations and potential progression or overlapping of the diseases. The other critical point of this case is to consider the poor response to standard DMARDs modifying agents, as well as to anti-TNF therapy, and as such, to switch between biological agents with different mechanisms of action. Further therapeutical goal could be B-cell depletion therefore. So, rituximab could be an eligible and available chance to achieve remission. Another possibility to control the common inflammatory pathway of JIA and SLE is blocking interleukin-6 (IL-6) with the soluble IL-6 receptor tocilizumab.
We believe that the better understanding of the common pathogenic pathways in JIA and SLE overlap could lead to the development of optimal therapeutic modalities and improved quality of life these patients.
